Isentress Tablet, Film Coated
NDC Package 68071-2113-6
Package Information
Isentress (raltegravir) tablets is iSENTRESS® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in patients 4 weeks of age and older.The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response [see Clinical Studies (14)]. This formulation utilizes a tablet, film coated delivery system. Marketed by Nucare Pharmaceuticals,inc., this product is identified by NDC 68071-2113 and is authorized under FDA application NDA022145.
Identification & Billing
- RxCUI: 744842 - raltegravir 400 MG Oral Tablet
- RxCUI: 744842 - raltegravir 400 MG (as raltegravir potassium 434.4 MG) Oral Tablet
- RxCUI: 744846 - Isentress 400 MG Oral Tablet
- RxCUI: 744846 - raltegravir 400 MG Oral Tablet [Isentress]
- RxCUI: 744846 - ISENTRESS 400 MG (as raltegravir potassium 434.4 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68071 - Nucare Pharmaceuticals,inc.
- 68071-2113 - Isentress
- 68071-2113-6 - 6 TABLET, FILM COATED in 1 BOTTLE
- 68071-2113 - Isentress
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68071-2113-6 identifies a specific commercial package of 6 tablet, film coated in 1 bottle of Isentress, a human prescription drug labeled by Nucare Pharmaceuticals,inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 6 billable units per package. This tablet, film coated is formulated for oral use and contains raltegravir potassium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nucare Pharmaceuticals,inc. on October 12, 2007. The current certification is valid through December 31, 2027.
How is this Nucare Pharmaceuticals,inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68071211306. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 6 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.